SSRI Study for Functional Dyspepsia (SS)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02153567|
Recruitment Status : Completed
First Posted : June 3, 2014
Last Update Posted : January 31, 2019
|First Submitted Date ICMJE||May 30, 2014|
|First Posted Date ICMJE||June 3, 2014|
|Last Update Posted Date||January 31, 2019|
|Actual Study Start Date ICMJE||December 6, 2013|
|Actual Primary Completion Date||December 31, 2018 (Final data collection date for primary outcome measure)|
|Current Primary Outcome Measures ICMJE
||To evaluate the change of serotonin and ghrelin level in blood plasma before and after treatment [ Time Frame: Week 8 ]
evaluate the change of serotonin and ghrelin level in blood plasma before and after treatment
|Original Primary Outcome Measures ICMJE
||To evaluate the change of serotonin and ghrelin level in blood plasma before and after treatment [ Time Frame: Week 8 ]|
|Change History||Complete list of historical versions of study NCT02153567 on ClinicalTrials.gov Archive Site|
|Current Secondary Outcome Measures ICMJE
|Original Secondary Outcome Measures ICMJE
||To measure expression of serotonin and ghrelin blood plasma, the rate of adequate relief using global symptom assessment, symptom scores and the fullness rating of the Fullness Rating Scale (FRS) during satiety test [ Time Frame: At 28 minute on satiety test ]|
|Current Other Pre-specified Outcome Measures||Not Provided|
|Original Other Pre-specified Outcome Measures||Not Provided|
|Brief Title ICMJE||SSRI Study for Functional Dyspepsia (SS)|
|Official Title ICMJE||Effect of Selective Serotonin Reuptake Inhibitor on Satiety Function in Patients With Functional Dyspepsia|
Functional dyspepsia is one of the commonest digestive disorders. The pathophysiology of functional dyspepsia (FD) is uncertain. Clinical experience and community studies show that FD is strongly associated with common mood disorders especially depression and anxiety disorders, which can be treated with serotonin selective uptake receptor (SSRI).
Our previous study shows that the relief of FD symptom has an association with the change of plasma serotonin and ghrelin profile. However, the correlation between plasma serotonin level in FD patients treated with SSRI is lacking in these studies.
Functional dyspepsia patients
Prince of Wales Hospital, Hong Kong
Escitalopram (Lexapro) 5mg daily for first 2 weeks, and then 10 mg daily for 8 weeks versus Placebo for 10 weeks
Double-blind randomized placebo-controlled trial
Number of subjects:72
- 36 patients (18 male and 18 female) and 36 age-and-sex-matched healthy controls
Functional dyspepsia patients age 18-60, with element of anxiety or depression
Duration of study: 1 June 2013 - 30 November 2015
Change of serotonin and ghrelin level in blood plasma after medication treatment
Rate of adequate relief using global symptom assessment and symptom scores
Number of visits: 2
Satiety test and ghrelin profile:
After an overnight fast, the patients are instructed to ingest Ensure® (1.06 kcal/ml; 22% fat, 64% carbohydrate, and 14% protein) at constant rate of 30ml/min for a fixed calorie test of 28 minutes (Total calorie: 890.4 kcal). They are required to complete a Fullness Rating Scale (FRS) at 3-min intervals (ie. 0min, 3min, 6min…). Initial Blood sample of 16 ml will be taken (10ml will be taken preprandially for storage in future identification of biomarkers for functional GI disorders and 6 ml for assay of ghrelin and serotonin profile). Another blood sample (6 ml) will be taken at 120min for assay of ghrelin and serotonin profile.
The test will be performed at baseline (V1) and after medication treatment (V2).
Baseline neuroimaging studies (female subjects only):
Analysis- We will compare the whole brain FA/ADC map and fiber tracts between different ROIs as stated above. The statistical group comparison of whole brain FA/ADC values will be performed following the voxel-based tract based spatial-statistics (TBSS), which is an automated method of comparing the FA values after aligning images from multiple subjects. The advantage of applying TBSS lies in the robust "voxel-wise" cross-subject statistics, better image alignment, and projecting data onto group-mean tract skeleton. Aside from the whole brain FA/ADC analysis, we also intend to compare the fiber density and FA/ADC values in each specific ROIs. The ROI in the DTI data will be identified by registering with the structural data and mapping the ROI segmentation results from the structural data. The whole brain tractography will be performed and the density of the fibers in each ROI will be calculated and compared between two groups. The mean FA/ADC values in each ROI will also be compared between two groups.
The tests will be performed at baseline (V1) for female patients and controls only.Functional neuroimaging assessment (female patients only) Functional MRI -resting state functional connectivity For resting-state fMRI scanning, subjects will be instructed to have their eyes closed for 6 minutes and hold still without falling asleep. Subjects considered not compliant with these instructions will be excluded from the study. Resting fMRI data will be collected by using a single-shot echo-planar sequence sensitive to BOLD contrast (TR: 2050ms, TE: 25ms, flip angle 90o, slab thickness: 150 mm, field of view: 205x205 mm, image matrix: 64x64, parallel imaging acceleration factor of 2) to acquire 150 dynamic scans under each condition. BOLD images acquired will have a nominal in-plane resolution of 3.2x3.2 mm and a temporal resolution of 2 s per dynamic scan.
Analysis- The functional brain connectivity will be derived from the resting state functional MRI (rs-fMRI) data and compared between two groups. In particular, the rs-fMRI data will be co-registered with the structural MRI data. Ninety-nine brain regions will be automatically partitioned by mapping with the Chinese brain atlas with 90 labeled regions. The correlation of the low frequency time series data will be calculated between every two regions among the 90 regions, based on which a connectivity matrix will be generated and thresholded to construct the functional brain connectivity network. The global, regional, and local network characteristics will then be derived and compared between two groups.
Magnetic Resonance Spectroscopy:
Localized proton MRS will be performed after structural images have been obtained to guide the positioning of volumes of interests in the left insula and bilateral pregenual anterior cingulate cortex and left primary somatosensory cortex. Signal reception for 1H-MRS will be achieved using the same 8-channel received-only head coil. Water-suppressed spectra will be acquired from each region measuring 2 x 2 x 2 cm3 using the point-resolved spectroscopic (PRESS) sequence (TR/TE 2000/23 ms). A short TE PRESS sequence will be employed to enable an optimal detection of metabolites of interest such as glutamate-glutamine (Glx) peaks. Optimization procedures for spectroscopy will comprised of automated receiver gain frequency adjustment, second-order shimming and gradient tuning. Water suppression will be achieved using an automated selective inversion recovery technique. From each region, 128 water-suppressed signals will be acquired at a spectral bandwidth of 1,000Hz. The averaged signals will be exported and processed on an off-line computer.
MRS Data Analysis Short TE spectra acquired will be analyzed using a fully automated and user-independent spectral software package LCModel, a frequency-domain postprocessing tool that is well suited to quantify complex signals Glx (ref). The advantage of LCModel is that it employs information from the whole chemical shift range of a spectrum to fit the amplitudes of the model spectra. The metabolites of interest in our study will be NAA, Cho, mI, Glx, glutamine, glutamate, GABA and creatinine. Metabolite ratios mI/Cr, Glx/Cr, NAA/Cho, NAA/Cr and Cho/Cr will be calculated based on peak concentration values obtained from LCModel analysis.
The test will be performed at baseline (V1) and after medication treatment (V2) for female patients only.
Randomization and unblinding of treatment arm
Randomization is performed for each gender independently, so that each gender group (male and female) consists of 9 patients in treatment arm and 9 patients in control arm.
The random allocation sequence is obtained from a computer-generated list of random numbers in blocks of 18. Concealed allocation is achieved by an independent staff who labels the Escitalopram 5mg/10mg and placebo according to the computer-generated list. The study arm allocated for each study number is printed and sealed in individual envelopes of consecutive study number.
After satiety test at baseline (V1), the research staff will dispense the sealed packaged study medication according to the patient's study number which is given in consecutive order according to patient's gender. Both the investigators, research staff and patients are not aware of the treatment assignments throughout the study.
At final visit (V2), the study arm that the patient is assigned to will be unblinded by opening the prepared sealed envelope of the patient's study number. Physician consultation will be given to decide further management of the disease based on patient's symptom response and current medication treatment. Further titration (either dose escalation or tapering) will be determined at the discretion of physician based on individual responses if the patient has been allocated to the Escitalopram group. The patient would continue his disease management in the hospital's specialty clinic after final visit (V2). Medication adherence is measured by pill counts at final visit (V2).
Follow-up questionnaire assessment:
The patients will report their individual dyspeptic and mood symptoms on a weekly basis until week 8 by completing the following self-administered questionnaires: FGISQ, BAI and BDI. ASI-R will only repeat at week 8.
|Study Type ICMJE||Interventional|
|Study Phase ICMJE||Phase 3|
|Study Design ICMJE||Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
|Study Arms ICMJE||
|Publications *||Not Provided|
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
|Recruitment Status ICMJE||Completed|
|Actual Enrollment ICMJE
|Original Estimated Enrollment ICMJE
|Actual Study Completion Date ICMJE||January 9, 2019|
|Actual Primary Completion Date||December 31, 2018 (Final data collection date for primary outcome measure)|
|Eligibility Criteria ICMJE||
|Ages ICMJE||18 Years to 60 Years (Adult)|
|Accepts Healthy Volunteers ICMJE||Yes|
|Contacts ICMJE||Contact information is only displayed when the study is recruiting subjects|
|Listed Location Countries ICMJE||Hong Kong|
|Removed Location Countries|
|NCT Number ICMJE||NCT02153567|
|Other Study ID Numbers ICMJE||SS|
|Has Data Monitoring Committee||Not Provided|
|U.S. FDA-regulated Product||Not Provided|
|IPD Sharing Statement ICMJE||
|Responsible Party||Justin Che-Yuen Wu, Chinese University of Hong Kong|
|Study Sponsor ICMJE||Chinese University of Hong Kong|
|Collaborators ICMJE||Not Provided|
|PRS Account||Chinese University of Hong Kong|
|Verification Date||January 2019|
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP